UMIN-CTR Clinical Trial
| Unique ID issued by UMIN | UMIN000042866 |
|---|---|
| Receipt number | R000048889 |
| Scientific Title | A Clinical Study to Explore Prediction of Response to Abemaciclib and Predictors of Intestinal Toxicity in ER-positive Metastatic Breast Cancer |
| Date of disclosure of the study information | 2020/12/28 |
| Last modified on | 2023/01/12 15:37:01 |
* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments
Basic information
Public title
A Clinical Study to Explore Prediction of Response to Abemaciclib and Predictors of Intestinal Toxicity in ER-positive Metastatic Breast Cancer
Acronym
A Clinical Study to Explore Prediction of Response to Abemaciclib and Predictors of Intestinal Toxicity in ER-positive Metastatic Breast Cancer
Scientific Title
A Clinical Study to Explore Prediction of Response to Abemaciclib and Predictors of Intestinal Toxicity in ER-positive Metastatic Breast Cancer
Scientific Title:Acronym
A Clinical Study to Explore Prediction of Response to Abemaciclib and Predictors of Intestinal Toxicity in ER-positive Metastatic Breast Cancer
Region
| Japan |
Condition
Condition
ER-positive Metastatic Breast Cancer
Classification by specialty
| Hematology and clinical oncology | Breast surgery |
Classification by malignancy
Malignancy
Genomic information
NO
Objectives
Narrative objectives1
This study aims to explore prediction of response to abemaciclib and predictors of intestinal toxicity in ER-positive metastatic breast cancer.
Basic objectives2
Safety,Efficacy
Basic objectives -Others
Trial characteristics_1
Exploratory
Trial characteristics_2
Others
Developmental phase
Not applicable
Assessment
Primary outcomes
･Time to Treatment Failure [ Time Frame: 2 years ]
･Incidence and severity of diarrhea [ Time Frame: Time Frame: 2 years ]
Key secondary outcomes
Objective Response Rate [ Time Frame: 2 years ]
･Progression Free Survival (PFS) [ Time Frame: 2 years ]
･Overall Survival [ Time Frame: 2 years ]
･Disease Control Rate [ Time Frame: 2 years ]
･Clinical Benefit Rate [ Time Frame: 2 years ]
･Incidence of serious adverse events and other adverse events of special interest [ Time Frame: Time Frame: 2 years ]
･Change in predominant enterotypes and diversity of fecal microbiota
[ Time Frame: Gut microbiota will be analyzed at the beginning, after 3 months of intervention, and after disease progression]
･Correlation with Dietary habits [ Time Frame: Lifestyle will be analyzed at the beginning ]
･Correlation with Physical activity level
[ Time Frame: Lifestyle will be analyzed at the beginning ]
･Change in Tumor Immune microenvironment system
[ Time Frame: Tumor Immune microenvironment system will be analyzed at the beginning, after 3 months of intervention, and after disease progression]
Base
Study type
Observational
Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment
Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10
Eligibility
Age-lower limit
| 20 | years-old | <= |
Age-upper limit
| Not applicable |
Gender
Male and Female
Key inclusion criteria
1) Patients must have histologically or cytologically confirmed invasive breast cancer, which is recurrent, unresectable or metastatic.
2) Either the primary tumor and/or metastatic tumor must be ER-positive on the most recent sample as defined below: Hormone receptor status: the invasive tumor must be ER- positive, or staining present in >=1% by immunohistochemistry (IHC)
3) HER2 status: the invasive tumor must be Human Epidermal Growth Factor Receptor 2-Negative (HER2-negative) by the ASCO CAP guideline.
4) Patients must have been judged by the treating physician to start administering abemaciclib
5) Prior biologic therapy: Patients must have discontinued all biologic therapy at least 21 days before registration.
6) Prior radiation therapy: Patients may have received prior radiation therapy in either the metastatic or early-stage setting. Radiation therapy must be completed at least 14 days prior to study registration.
7) Patients on bisphosphonates or RANK-L inhibitors may continue receiving these therapies during study treatment. There is no washout period required between the last dose of these therapies and the start of abemaciclib.
8) The patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0-1
9) Patients must have normal organ and marrow function as defined below:
(1)Absolute neutrophil count >=1500/mm3
(2)Platelets >=100,000/mm3
(3)Hemoglobin >=8 g/dL
(4)Total bilirubin <=1.5x the upper limit of normal (ULN)
(5)Serum creatinine <=1.5 mg/dL OR calculated GFR >=60mL/min
(6)Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) <=3
times the upper limit of normal. For patients with documented liver
metastases, AST/ALT <= 5.0 times the upper limit of normal.
10) The patient must be >=20years old
11) Capable of understanding and complying with the protocol and has signed the informed consent document.
12) Able to swallow study drug.
Key exclusion criteria
1)Undergone major surgery within 14 days of the first dose of study drug.
2)Received another investigational agent within 14 days of the first dose of study drug. (Within 21 days for investigational agent with myelosuppressive agent.)
3)Received myelosuppressive chemotherapy for metastatic setting.
4)Has any severe concurrent disease that renders the patient inappropriate for enrollment in the opinion of the investigator.
5)Patients with active bacterial or fungal infections or detectable viral infections.
6)Documented brain metastases that are symptomatic, or require therapy to control symptoms. Patients who have completed treatment for brain metastasis such as surgery and radiation therapy and have no symptoms can be registered.
7)Pregnant women and lactating women are excluding from the study.
8)Individuals with a history of a second malignancy are ineligible except for the following circumstances: individuals with a history of other malignancies are eligible if they have been disease-free for at least 5 years and are deemed by the investigator to be at low risk for recurrence of that malignancy. Patients with cervical cancer, or non-melanoma cancer of the skin. Patients with other cancers diagnosed within the past 5 years and felt to be at low risk of recurrence should be discussed with the principle investigator to determine eligibility.
9)Have been previously treated with palbociclib (excluding discontinuation due to toxicity)
10)Patients with constipation of Grade 2 or higher
11)The patient has serious uncontrolled preexisting medical condition(s) that in the judgement of the investigator, would preclude participation in this study (for example, severe renal impairment [e.g. estimated creatinine clearance <30ml/min],history of major surgical resection involving the stomach or small bowel, or a preexisting chronic condition resulting in baseline Grade 2 or higher diarrhea).
12)Patients with interstitial pneumonia.
Target sample size
40
Research contact person
Name of lead principal investigator
| 1st name | Kosuke |
| Middle name | |
| Last name | Kawaguchi |
Organization
Kyoto University Hospital
Division name
Breast Surgery Department
Zip code
606-8507
Address
54 Kawaharacho, Shogoin, Sakyo-ku, Kyoto 606-8507
TEL
075-751-3660
kkosuke@kuhp.kyoto-u.ac.jp
Public contact
Name of contact person
| 1st name | Norihiko |
| Middle name | |
| Last name | Kitamura |
Organization
Kyoto Breast Cancer Research Network (KBCRN)
Division name
Clinical Trial Management
Zip code
601-8001
Address
Nakaya Building 1F, 1-10 Muromachi, Higashikujo, Minami-ku, Kyoto 601-8001
TEL
075-585-7861
Homepage URL
kitamura@kyoto-breast-cancer.org
Sponsor or person
Institute
Kyoto Breast Cancer Research Network (KBCRN)
Institute
Department
Personal name
Funding Source
Organization
Eli Lilly Japan K.K.
Organization
Division
Category of Funding Organization
Profit organization
Nationality of Funding Organization
Japan
Other related organizations
Co-sponsor
Name of secondary funder(s)
IRB Contact (For public release)
Organization
Kyoto University Graduate School and Faculty of Medicine, Ethics Committee
Address
Yoshida-Konoe-cho, Sakyo-ku, Kyoto 606-8501, JAPAN
Tel
075-753-4680
ethcom@kuhp.kyoto-u.ac.jp
Secondary IDs
Secondary IDs
NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW
Institutions
Institutions
京都大学医学部附属病院（京都府）
埼玉県立がんセンター（埼玉県）
社会医療法人博愛会 相良病院（鹿児島県）
社会医療法人神鋼記念会 神鋼記念病院（兵庫県）
公益財団法人 天理よろづ相談所病院（奈良県）
滋賀県立総合病院（滋賀県）
兵庫県立尼崎総合医療センター（兵庫県）
公益財団法人 田附興風会 医学研究所 北野病院（大阪府）
日本赤十字社 和歌山医療センター（和歌山県）
埼玉医科大学国際医療センター（埼玉県）
Other administrative information
Date of disclosure of the study information
| 2020 | Year | 12 | Month | 28 | Day |
Related information
URL releasing protocol
Publication of results
Unpublished
Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description
Progress
Recruitment status
No longer recruiting
Date of protocol fixation
| 2020 | Year | 10 | Month | 01 | Day |
Date of IRB
| 2020 | Year | 12 | Month | 14 | Day |
Anticipated trial start date
| 2021 | Year | 01 | Month | 04 | Day |
Last follow-up date
| 2024 | Year | 01 | Month | 31 | Day |
Date of closure to data entry
| 2024 | Year | 01 | Month | 31 | Day |
Date trial data considered complete
| 2024 | Year | 04 | Month | 30 | Day |
Date analysis concluded
| 2024 | Year | 07 | Month | 31 | Day |
Other
Other related information
Study Design: Prospective cohort study
Among patients who decided to start treatment with abemaciclib will be included. Of these patients, those who have provided written informed consent will be registered.
Management information
Registered date
| 2020 | Year | 12 | Month | 28 | Day |
Last modified on
| 2023 | Year | 01 | Month | 12 | Day |
Link to view the page
Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000048889
